英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

containerize    音标拼音: [kənt'enɚ,ɑɪz]

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Metastatic colorectal cancer: ESMO Clinical Practice Guideline for . . .
    Figure 1 Management of mCRC potentially amenable to locoregional therapy Purple: algorithm title; blue: systemic anticancer therapy or their combination; turquoise: non-systemic anticancer therapies or combination of treatment modalities; white: other aspects of management and non-treatment aspects CEA, carcinoembryonic antigen; ChT, chemotherapy; CRLM, colorectal liver metastasis; dMMR, MMR
  • Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin . . .
    To investigate whether intermittent treatment after an induction phase of first-line schedule of fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus panitumumab (PAN) prevents or delays the onset of resistance and improves safety and compliance with treatment in patients with unresectable RAS BRAF wild-type (wt) metastatic colorectal cancer (mCRC)
  • U. S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen . . .
    BRAFTOVI ® (encorafenib) is indicated, in combination with cetuximab and fluorouracil-based chemotherapy, for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-authorized test
  • ESMO 2026 Guideline: Redefining the Management of Metastatic Colorectal . . .
    Metastatic colorectal cancer (mCRC) represents a complex and biologically diverse disease in which treatment decisions increasingly depend on molecular characteristics, disease burden, and patient-specific factors
  • Management of BRAF-mutant metastatic colorectal cancer: a review of . . .
    Herein, we review the clinical and translational literature on the role of the BRAF V600E mutation in the pathogenesis of mCRC, its mechanisms as a prognostic marker, and its potential utility as a predictive marker of treatment response We then summarize the current evidence-based recommendations for management of BRAF V600E-mutated mCRC, with a focus on recent clinical research advances in
  • FDA Approves Encorafenib Combination for BRAF V600E . . . - Pharmacy Times
    Encorafenib is an oral small molecule kinase inhibitor that targets BRAF V600E and is used for various cancer types It received initial approval in 2024 in combination with cetuximab and mFOLFOX6 (leucovorin calcium [folinic acid], fluorouracil, and oxaliplatin) for the treatment of patients with mCRC with a BRAF V600E mutation
  • ASCO 2025: metastatic colorectal cancer—focus on precision oncology
    Introduction According to current European Society for Medical Oncology (ESMO) living guidelines, fit patients should be offered a combination of chemotherapy and a biologic agent as first-line therapy In RAS wild-type (wt) and BRAF wt metastatic colorectal cancer (mCRC), tumor sidedness is a relevant parameter for selecting optimal therapy
  • Amivantamab plus FOLFOX or FOLFIRI in RAS BRAF. . . : Journal of Clinical . . .
    In an earlier report, ami plus FOLFOX or FOLFIRI demonstrated rapid and durable antitumor activity among participants (pts) with RAS BRAF wild-type (WT) metastatic colorectal cancer (mCRC), resulting in their potential eligibility for curative-intent surgery (Pietrantonio ESMO 2024) Here, we present longer follow-up data
  • Potential new first-line treatment strategy for patients with BRAF . . .
    BREAKWATER: supporting a potential new first-line standard of care for previously untreated patients with BRAF V600E-mutant mCRC BEAKWATER Cohort 3 included 147 patients who were randomly assigned to receive the investigational combination (73 patients), or standard therapy (74 patients)
  • U. S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen . . .
    BRAFTOVI ® (encorafenib) is indicated, in combination with cetuximab and fluorouracil-based chemotherapy, for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF





中文字典-英文字典  2005-2009